These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16231045)

  • 41. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation, calibration, and specificity of quantitative D-dimer assays.
    Dempfle CE
    Semin Vasc Med; 2005 Nov; 5(4):315-20. PubMed ID: 16302152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Validation, updating and impact of clinical prediction rules: a review.
    Toll DB; Janssen KJ; Vergouwe Y; Moons KG
    J Clin Epidemiol; 2008 Nov; 61(11):1085-94. PubMed ID: 19208371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In-house validation and quality control of real-time PCR methods for GMO detection: a practical approach.
    Ciabatti I; Froiio A; Gatto F; Amaddeo D; Marchesi U
    Dev Biol (Basel); 2006; 126():79-86; discussion 324-5. PubMed ID: 17058483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The application of gene therapy in China.
    Peng Z; Yu Q; Bao L
    IDrugs; 2008 May; 11(5):346-50. PubMed ID: 18465676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An inventory of shedding data from clinical gene therapy trials.
    Schenk-Braat EA; van Mierlo MM; Wagemaker G; Bangma CH; Kaptein LC
    J Gene Med; 2007 Oct; 9(10):910-21. PubMed ID: 17880045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current separation and detection methods in microdialysis the drive towards sensitivity and speed.
    Guihen E; O'Connor WT
    Electrophoresis; 2009 Jun; 30(12):2062-75. PubMed ID: 19582708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene doping.
    Harridge SD; Velloso CP
    Essays Biochem; 2008; 44():125-38. PubMed ID: 18384287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How to standardize the multiplicity of methods to evaluate natural antioxidants.
    Frankel EN; Finley JW
    J Agric Food Chem; 2008 Jul; 56(13):4901-8. PubMed ID: 18553885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test.
    Glorieux G; Schepers E; Schindler R; Lemke HD; Verbeke F; Dhondt A; Lameire N; Vanholder R
    Nephrol Dial Transplant; 2009 Feb; 24(2):548-54. PubMed ID: 18768583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ELISA microarray technology as a high-throughput system for cancer biomarker validation.
    Zangar RC; Daly DS; White AM
    Expert Rev Proteomics; 2006 Feb; 3(1):37-44. PubMed ID: 16445349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improvement of the decision efficiency of the accuracy profile by means of a desirability function for analytical methods validation. Application to a diacetyl-monoxime colorimetric assay used for the determination of urea in transdermal iontophoretic extracts.
    Rozet E; Wascotte V; Lecouturier N; Préat V; Dewé W; Boulanger B; Hubert P
    Anal Chim Acta; 2007 May; 591(2):239-47. PubMed ID: 17481415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Purification of retroviral vectors for clinical application: biological implications and technological challenges.
    Rodrigues T; Carrondo MJ; Alves PM; Cruz PE
    J Biotechnol; 2007 Jan; 127(3):520-41. PubMed ID: 16950534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
    Stubenrauch K; Wessels U; Lenz H
    J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Validation protocol and analytical quality in biological monitoring of occupational exposure to antineoplastic drugs.
    Turci R; Sottani C; Schierl R; Minoia C
    Toxicol Lett; 2006 Apr; 162(2-3):256-62. PubMed ID: 16246507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sample to sample carryover: a source of analytical laboratory error and its relevance to integrated clinical chemistry/immunoassay systems.
    Armbruster DA; Alexander DB
    Clin Chim Acta; 2006 Nov; 373(1-2):37-43. PubMed ID: 16777083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic engineering and human disease.
    Yarmush ML; Berthiaume F
    Nat Biotechnol; 1997 Jun; 15(6):525-8. PubMed ID: 9181573
    [No Abstract]   [Full Text] [Related]  

  • 59. Evolution of fit-for-purpose biomarker validations: an LBA perspective.
    Neely RJ
    Bioanalysis; 2018 Jun; 10(12):905-907. PubMed ID: 29923756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Calcitonin: chemistry, immuno- and bio-assay effects in man.
    Angyal A; Boyd G; Byfield PG; Caffrey J; Clark MB; Foster GV; Galante L; Gay F; Gudmundsson TV; Horton RE; Joplin GF; Kalu D; MacIntyre I; Moseley J; Fraser TR; Nadarajah A; Woodhouse NJ
    J Physiol; 1969 May; 202(1):21P. PubMed ID: 5770890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.